Y Intercept Hong Kong Ltd Grows Stock Holdings in Edwards Lifesciences Corporation $EW

Y Intercept Hong Kong Ltd lifted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 534.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 168,378 shares of the medical research company’s stock after acquiring an additional 141,843 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Edwards Lifesciences were worth $13,169,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $266,000. Perigon Wealth Management LLC lifted its position in shares of Edwards Lifesciences by 6.9% in the first quarter. Perigon Wealth Management LLC now owns 4,325 shares of the medical research company’s stock valued at $313,000 after acquiring an additional 278 shares in the last quarter. Sequoia Financial Advisors LLC lifted its stake in shares of Edwards Lifesciences by 190.9% during the first quarter. Sequoia Financial Advisors LLC now owns 23,495 shares of the medical research company’s stock valued at $1,703,000 after buying an additional 15,417 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Edwards Lifesciences by 15.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 68,013 shares of the medical research company’s stock worth $4,823,000 after purchasing an additional 8,915 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after buying an additional 145 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of several recent research reports. Canaccord Genuity Group increased their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a report on Friday, July 25th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday. Truist Financial lifted their target price on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a “hold” rating in a research report on Friday, July 25th. Stifel Nicolaus set a $85.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Monday, September 22nd. Finally, JPMorgan Chase & Co. increased their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $87.06.

Edwards Lifesciences Stock Down 0.5%

NYSE EW opened at $76.15 on Monday. The stock has a 50 day moving average price of $77.37 and a 200-day moving average price of $76.48. Edwards Lifesciences Corporation has a one year low of $64.89 and a one year high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The company has a market capitalization of $44.70 billion, a P/E ratio of 10.96, a P/E/G ratio of 3.65 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business’s revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the business earned $0.70 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.34% of the stock is owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.